New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2014
07:35 EDTNLNKNewLink Genetics price target raised to $35 from $23 at Canaccord
Canaccord is more optimistic that the P3 IMPRESS trial of HyperAcute Pancreas in resected pancreatic cancer could meet its primary endpoint of an improvement in overall survival vs. placebo following a management meeting. Shares are Buy rated.
News For NLNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
11:03 EDTNLNKOptions with increasing call volume
Options with increasing call volume and volatility; GOLD EA IAG TMV MFLX AUY O NLNK LOCK
February 2, 2016
14:52 EDTNLNKZika virus acquired through sexual transmission reported in Dallas
Dallas County Health and Human Services announced it has received confirmation from the Centers for Disease Control and Prevention of the first Zika virus case acquired through sexual transmission in Dallas County in 2016. The patient was infected with the virus after having sexual contact with an ill individual who returned from a country where Zika virus is present, DCHHS reported. Publicly traded companies working on combating Zika include Inovio (INO), Cerus (CERS), NewLink (NLNK) and Intrexon (XON).
12:56 EDTNLNKMizuho downplays near-term Zika revenue potential for NewLink, Intrexon
The Zika virus and its link to microcephaly and fetal brain damage have exploded into public view and lead to several drugmakers announcing plans to fight the disease, but Mizuho analyst Eric Criscuolo downplayed the potential for Zika to truly move the needle for companies in the space in the near-term. PERIPHERAL OPPORTUNITIES: NewLink (NLNK) announced plans to develop treatment options for the Zika virus as the disease was declared a global health emergency by the World Health Organization this week. While the company "could" secure funding and partnerships for the project, Criscuolo does not view NewLink's Zika plans as core to its investment story, encouraging investors to instead evaluate the company on the basis of its HyperAcute and IDO programs. Meanwhile, Intrexon's (XON) efforts in mosquito population control have also gained attention amid the rise of Zika, whose primary transmission vector is the mosquito. Though even a small slice of global mosquito spending would represent "significant" revenue for Intrexon, Criscuolo cautions that the company's program is still in early stages, with attempts at a wider rollout likely encountering political, biological, financial and public opinion hurdles. Separately, the analyst said he wouldn't be surprised to see OraSure (OSUR) also attempt to develop a Zika test given the company's response to Ebola last year, though as with NewLink, Criscuolo believes any such effort would be peripheral to OraSure's primary businesses. OTHERS TO WATCH: Other publicly traded companies involved in combating Zika include Inovio (INO) and Cerus (CERS). PRICE ACTION: Shares of NewLink are up roughly 5% to $25.63. Meanwhile, Intrexon has slipped 5.5% on Tuesday afternoon but is still up 15% over the last five trading days. Among others with links to Zika, OraSure is up fractionally, Inovio has fallen 7% and Cerus has dipped 1.4% this afternoon.
07:14 EDTNLNKNewLink Genetics announces project to develop treatment options for Zika virus
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use